ABSTRACT
Background Detecting early-stage Alzheimer’s disease in clinical practice is difficult due to a lack of efficient and easily administered cognitive assessments that are sensitive to very mild impairment, a likely contributor to the high rate of undetected dementia.
Objective Here, we aim to identify groups of cognitive assessment features optimized for detecting mild impairment that can be used in routine screening. We also compare the efficacy of classifying impairment using either a two-class (impaired vs non-impaired) or three-class approach.
Methods Supervised feature selection methods generated groups of cognitive measurements targeting impairment defined at CDR 0.5 and above. Random forest classifiers then generated predictions of impairment for each group using highly stochastic cross-validation, with group outputs examined using general linear models.
Results The strategy of combining impairment levels for two-class classification resulted in significantly higher sensitivities and NPVs, two metrics useful in clinical screening, compared to the three-class approach. Just four neuropsychological features (delayed WAIS Logical Memory, trail-making, patient and informant memory questions), able to be administered in approximately 15 active minutes (∼30 minutes with delay), enabled classification sensitivity of 94.53% (88.43% PPV) with the addition of four more features significantly increasing sensitivity to 95.18% (88.77% PPV) when added to the model as a second classifier.
Conclusion The high detection rate paired with the minimal assessment time of the four identified features may act as an effective starting point when screening for cognitive impairment defined at CDR 0.5 and above.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been found to be exempt from IRB oversight
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
